AAN17: Phase III study reports the positive effects of an “old” drug for the treatment of advanced Parkinson’s disease

Written by Jonathan Wilkinson

The results of a Phase III study have provided evidence that the drug apomorphine, first produced in 1865, could be effective in the management of advanced Parkinson’s disease. The study will be presented at the American Academy of Neurology’s 69th Annual Meeting in Boston (MA, USA), April 22–28, 2017. The oral drug levodopa is the current drug of choice for the treatment of Parkinson’s disease. However, over time the effectiveness of the medication decreases, leading sufferers to experience “off time” when periods of immobility occur. Apomorphine has been used since the 1950s to treat advanced Parkinson’s disease. In the 1990s,...

To view this content, please register now for access

It's completely free